Centogene N.V. (CNTG)
| Previous close | 3.0400 |
| Open | 3.1500 |
| Bid | 1.2800 x 2900 |
| Ask | 3.1800 x 1200 |
| Day's range | 3.0400 - 3.2000 |
| 52-week range | 3.0100 - 11.9500 |
| Volume | |
| Avg. volume | 10,953 |
| Market cap | 83.921M |
| Beta (5Y monthly) | -1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2020 |
| Earnings date | 14 June 2022 - 20 June 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.03 |
- GlobeNewswire
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced that Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites investors to participate via virtual one-on-one meetings. Please see additional details below: H.C. Wainwright Global I
- Simply Wall St.
Centogene (NASDAQ:CNTG) investors are sitting on a loss of 66% if they invested a year ago
Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of Centogene N.V...
- GlobeNewswire
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare neurodegenerative diseasesThe global market access and expansion partnership initially established in 2015 aims to provide an efficient and timely diagnosis to patientsDiagnosis remains crucial for patients, leading them towards suitable readily available t
